Health & Fitness
Health and Fitness
Health and Fitness
Tue, September 8, 2009
Sun, September 6, 2009
Fri, September 4, 2009
Thu, September 3, 2009 AspenBio Pharma, Inc.: AspenBio Pharma to Present at the Annual Baird Healthcare Conference
CASTLE ROCK, CO--(Marketwire - September 3, 2009) - AspenBio Pharma, Inc. (
AspenBio Pharma's management is scheduled to present at 10:30 a.m. Eastern time, with one-on-one meetings held throughout the day. Management will discuss the company's progress, including its recently filed Premarket Notification 510(k) with the U.S. Food and Drug Administration ("FDA") for AppyScore, the first blood-based test designed to rule out the diagnosis of human appendicitis.
The test is expected to be used in combination with other modalities currently used in diagnosing appendicitis. AppyScore's target market is the 5.6 million people who enter hospital Emergency Departments annually and have blood and associated lab work performed to aid in the diagnosis of abdominal pain.
AspenBio is also advancing a new class of drugs that replace natural reproductive hormones for animals of economic importance. The company has a development and marketing agreement with Novartis Animal Health (
Leading the presentation will be the company's executive chairman and CEO, Daryl Faulkner, who was previously president, CEO and board member of Digene Corp., a Nasdaq-traded company prior to its acquisition by Qiagen.
For more information about the conference or to schedule a one-on-one meeting with the company, contact Baird at 800-RW-BAIRD (800-792-2473).
About Baird
Baird is an employee-owned, international wealth management, capital markets, private equity and asset management firm with offices in the United States, Europe and Asia. Established in 1919, Baird has more than 2,400 associates serving the needs of individual, corporate, institutional and municipal clients. Baird oversees and manages client assets of more than $62 billion. Baird's Research Department consists of 110 research professionals, including 37 senior analysts, covering more than 535 U.S. companies. Baird analysts have been recognized repeatedly in The Wall Street Journal's annual "Best on the Street" survey and honored by StarMine as top analysts. For more information, please visit Baird's Web site at [ www.rwbaird.com ].
About AspenBio Pharma, Inc.
AspenBio Pharma, Inc. (
Forward-Looking Statements
This news release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not guarantees of the future as there are a number of meaningful factors that could cause the company's actual results to vary materially from those indicated by such forward-looking statements. These statements are based on certain assumptions made based on experience, expected future developments and other factors the company believes are appropriate in the circumstances. Meaningful factors, which could cause actual results to differ from expectations, many of which are beyond the control of the company, include, but are not limited to, our ability to successfully complete the clinical trial data assessments required for FDA submission, obtain FDA approval for, cost effectively manufacture and generate revenues from, the appendicitis test in development, as well as the animal products and other new products developed by the company, and our ability to retain the scientific management team to advance the products in development, execute agreements to provide the company with rights to meet its objectives, overcome adverse changes in market conditions and the regulatory environment, and obtain and enforce intellectual property rights. The company does not intend (and is not obligated) to update publicly any such forward-looking statements. For other factors that may impact such forward-looking statements, reference is made to our annual and quarterly reports filed with the Securities and Exchange Commission.
